about
Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapyEfficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phaseEffects of Evolocumab on Vitamin E and Steroid Hormone Levels: Results From the 52-Week, Phase 3, Double-Blind, Randomized, Placebo-Controlled DESCARTES Study.Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial.Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease.Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial.A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.Rationale and Design of LAPLACE-2: A Phase 3, Randomized, Double-Blind, Placebo- and Ezetimibe-Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hypercholesterolemia on Background Statin TherapyEffects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trialInhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trialDesign and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapyEfficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials
P50
Q33161987-58F02322-DE12-47E8-BADD-B0D214CC5909Q34043472-EA550E32-6BE7-4628-A58A-9174FFC83C7DQ35141471-E6ED3651-5B33-4DAF-B81B-E66522ECE2EFQ35141476-F33E9C40-E0F8-4158-8C88-BDEA15B96A5CQ38406987-CBC456A7-1826-4409-85DB-436E4E3B9ACBQ38430399-062C9EEB-52AA-465D-A360-8D2D723FB59AQ38440924-59CC410C-71B0-4DFF-8BD9-8810FA394B62Q43919586-655FDB40-FA0E-49C3-B9ED-90363F9BA516Q45904176-44917AD7-73E1-4222-9279-1970599E1E95Q45970166-9D1E0ED5-FEFB-4007-AA27-BD294EDEF82EQ46383780-92B63D05-1CBB-4BEF-AE49-F5F33D13E492Q46576382-98B2C4F3-A16B-40A5-9484-DA78DE477B05Q46576710-D8D225E5-9A10-41CB-85A3-54D4A6D7A84FQ57568884-975A6C0C-C0CE-4D42-9D04-8D470CE827D0Q79533790-022AC453-177F-431C-95E2-636893549E30Q85678153-94973F15-40FD-47B7-92D3-7DC6EE3130F1Q87193755-9ABB4CDD-B691-48A5-9296-2348FBEACE3DQ87405997-258836D0-BFBE-405F-A444-B6255D1C6B4C
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Robert Scott
@ast
Robert Scott
@en
Robert Scott
@es
Robert Scott
@nl
type
label
Robert Scott
@ast
Robert Scott
@en
Robert Scott
@es
Robert Scott
@nl
prefLabel
Robert Scott
@ast
Robert Scott
@en
Robert Scott
@es
Robert Scott
@nl
P106
P31
P496
0000-0001-8266-1061